People news from the 04/28/06 News Brief

MANUFACTURERS Astellas Pharma has promoted EVP Masafumi Nogimori to CEO. Toichi Takenaka, current president and CEO, will become co-chairman. Hatsuo Aoki, now chairman, will also be co-chairman. The changes will take effect on June 27 and are subject to the approval of the board of directors meeting to be held on the same day. ZymoGenetics has hired Michael Dwyer as SVP of marketing and sales and as a member of the executive management committee. Dwyer has nearly 30 years’ experience in biologic and pharmaceutical marketing and sales, with expertise in marketing execution, sales management and sales operations. He will be responsible for continuing to build ZymoGenetics’ sales, marketing and operations/logistics team in preparation for anticipated launch of recombinant human thrombin (rhThrombin) in late 2007. AGENCIES WeissComm Partners, a communications agency focused on the healthcare industry, has appointed Jennifer Gottlieb managing director and head of its East Coast operations in New York. Gottlieb joins from Cohn & Wolfe, where she was EVP and managing director of its 75-person New York healthcare practice. At WeissComm, she will manage all aspects of the company’s New York office operations. SUPPLIERS MedPoint Communications, a provider of communications and eMedia services to the biopharmaceutical industry, announced that John Moen has been named director of creative and editorial services. MEDIA Satish Garg, professor of medicine and pediatrics at the Barbara Davis Center for Childhood Diabetes of the University of Colorado at Denver, has been appointed the new editor in chief of Diabetes Technology & Therapeutics, a Medline journal published by Mary Ann Liebert. Jay Skyler, professor of medicine, pediatrics and psychology at the University of Miami, joins as associate editor. Diabetologists including John Buse, Lois Jovanovic, Howard Wolpert and H. Peter Chase have also joined the editorial team.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.